Cellosaurus logo
expasy logo

Cellosaurus U-CH2 (CVCL_4989)

[Text version]
Cell line name U-CH2
Synonyms UCH-2; UCH2
Accession CVCL_4989
Resource Identification Initiative To cite this cell line use: U-CH2 (RRID:CVCL_4989)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Doubling time: 4 days (PubMed=26183925); ~5-7 days (DSMZ=ACC-749); 3 days (Chordoma_Foundation).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
HLA typing Source: Chordoma_Foundation
Class I
Class II
Genome ancestry Source: PubMed=30894373

Origin% genome
Native American0.92
East Asian, North0
East Asian, South0.34
South Asian1.36
European, North67.93
European, South29.44
Disease Sacral chordoma (NCIt: C129927)
Chordoma (ORDO: Orphanet_178)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 72Y
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; DSMZ; PubMed=21253487; PubMed=26183925; PubMed=27102572; PubMed=28835717

D18S5112,18 (PubMed=26183925; PubMed=27102572; PubMed=28835717)
12,17.3 (DSMZ)
D19S43315.2,17 (PubMed=26183925; PubMed=27102572)
16,17 (DSMZ)
Penta D12,13
Penta E12,15
TH016 (Cosmic-CLP)
6,9.3 (PubMed=21253487)
9.3 (ATCC; DSMZ; PubMed=26183925; PubMed=27102572)

Run an STR similarity search on this cell line
Web pages https://www.chordomafoundation.org/research/disease-models/u-ch2/

PubMed=21253487; DOI=10.1155/2010/630129
Bruderlein S., Sommer J.B., Meltzer P.S., Li S., Osada T., Ng D., Moller P., Alcorta D.A., Kelley M.J.
Molecular characterization of putative chordoma cell lines.
Sarcoma 2010:630129.1-630129.14(2010)

PubMed=26183925; DOI=10.1158/0008-5472.CAN-14-3270
von Witzleben A., Goerttler L.T., Marienfeld R., Barth H., Lechel A., Mellert K., Bohm M., Kornmann M., Mayer-Steinacker R., von Baer A., Schultheiss M., Flanagan A.M., Moller P., Bruderlein S., Barth T.F.E.
Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4/6 cell-cycle pathway.
Cancer Res. 75:3823-3831(2015)

PubMed=27102572; DOI=10.1002/path.4729
Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H., Zuercher W.J., Turlais F., Ye H., Leite A.P., Smith J.A., Leithner A., Moller P., Bruderlein S., Guppy N., Amary F., Tirabosco R., Strauss S.J., Pillay N., Flanagan A.M.
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
J. Pathol. 239:320-334(2016)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28515451; DOI=10.1038/s41598-017-02174-5
Jager D., Barth T.F.E., Bruderlein S., Scheuerle A., Rinner B., von Witzleben A., Lechel A., Meyer P., Mayer-Steinacker R., Baer A.V., Schultheiss M., Wirtz C.R., Moller P., Mellert K.
HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.
Sci. Rep. 7:2032-2032(2017)

PubMed=28835717; DOI=10.1038/s41598-017-10044-3
Bosotti R., Magnaghi P., Di Bella S., Cozzi L., Cusi C., Bozzi F., Beltrami N., Carapezza G., Ballinari D., Amboldi N., Lupi R., Somaschini A., Raddrizzani L., Salom B., Galvani A., Stacchiotti S., Tamborini E., Isacchi A.
Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.
Sci. Rep. 7:9226-9226(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cell line collections (Providers) ATCC; CRL-3218
Cell line databases/resources Cell_Model_Passport; SIDM01185
Cosmic-CLP; 1503373
DepMap; ACH-002204
DSMZCellDive; ACC-749
Chemistry resources PharmacoDB; UCH2_1627_2019
Encyclopedic resources Wikidata; Q54973617
Gene expression databases GEO; GSM1670565
GEO; GSM1673847
GEO; GSM1673848
Polymorphism and mutation databases Cosmic; 2663858
Proteomic databases PRIDE; PXD030304
Entry history
Entry creation04-Apr-2012
Last entry update21-Mar-2023
Version number28